International Journal of Obstetric Anesthesia
Volume 16, Issue 4 , Pages 354-357 , October 2007

Recombinant factor VIIa should be used in massive obstetric haemorrhage

    Proposer:
  • Felicity Plaat

      Affiliations

    • Corresponding Author InformationCorrespondence to: Felicity Plaat, Department of Anaesthetics, Queen Charlotte’s Hospital, London.

References 

  1. O’Connell , Wood JJ, Wise RP, et al. Thromboembolic adverse effects after use of recombinant human coagulation factor VIIa. JAMA. 2006;295:293–298
  2. von Heyman C, Hotz H, Konertz W, et al. Successful treatment of refractory bleeding with recombinant factor Vila after redo coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2002;16:615–616
  3. Kastrup M, von Heymann C, Hotz H, et al. Recombinant factor Vila after aortic valve replacement in a patient with osteogenesis imperfecta. Ann Thorac Surg. 2002;74:910–912
  4. Tobias JD, Berkenbosch JW, Muruve NA, Schmaltz RA. Correction of a coagulopathy using recombinant factor VII before removal of an intra-aortic balloon pump (IABD). J Cardiothorac Vasc Anesth. 2002;16:612–614
  5. Dutton RP, Hess JR, Scalea TM. Recombinant factor VIIa in control of haemorrhage; early experience in critically ill trauma patients. J Clin Anesth. 2003;15:184–188
  6. Sharmi VM, Caldwell SS, Hespenheide EE, et al. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl. 2003;9:138–143
  7. Svartholm E, Annerhagen V, Lanne T. Treatment of bleeding in severe necrotizing pancreatitis with recombinant factor VIIa. Anesthesiology. 2002;96:1528
  8. Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel, randomized, placebo-controlled, double-blind clinical trials. J Trauma. 2005;59:8–18
  9. Moscardo F, Peres F, de la Rubia J, et al. Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. Br J Haematol. 2001;113:174–176
  10. UNICEF. The progress of the nations 2001. New York: United Nations Children’s fund; 2001.
  11. New estimates of maternal mortality. Wkly Epidemiol Rec 1996; 71: 97–100.
  12. Waterstone M, Bewley S, Wolfe C. Incidence and predictors of severe obstetric morbidity: a case control study. Br Med J. 2001;322:1089–1093
  13. Jouppila P. Postpartum haemorrhage. Curr Opin Obstet Gynecol. 1995;70:446–450
  14. Dildy GA. Postpartum haemorrhage: new management options. Clin Obstet Gynecol. 2002;45:330–344
  15. Mousa HA, Alfirevic Z. Treatment for primary postpartum haemorrhage. Cochrane Database of Systematic Reviews 2007 Issue 1.
  16. SHOT Annual Report 2005. www.shot-uk.org.
  17. Llewelyn CA, Hewitt PE, Knight RSG, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. The Lancet. 2004;363:417–421
  18. Gabriel DA, Li X, Monroe DM, Roberts HR. Recombinant human factor VIIa, (rFVIIa) can activate FX on activated platelets. J Thromb Haemost. 2004;2:1816–1822
  19. Kjalke M, Johannessen M, Hedner U. Effect of recombinant factor VIIa (NovoSeven) on thrombocytopenia-like conditions in vitro. Semin Haematol. 2001;38:15–20
  20. Gabriel D, Muga K, Boothroyd E. The effect of fibrin structure on fibrinolysis. J Biol Chem. 1992;267:259–263
  21. Erhardtsen E, Nony P, Dechavanne M, et al. The effect of recombinant factor VIIa (NovoSevenTM) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0. Blood Coagul Fibrinolysis. 1998;9:741–748
  22. O’Connell NM, Perry DJ, Hodgson AJ, et al. recombinant FVIIa in the management of uncontrolled haemorrhage. Transfusion. 2003;43:1711–1716
  23. Payne EM, Brett SJ, Laffan MA. Efficiency of recombinant activated factor VII in unselected patients with uncontrolled haemorrhage: a single centre experience. Blood Coagul Fibrinolysis. 2006;17:397–402
  24. Haynes J, Laffan M, Plaat F. Use of recombinant activated factor VII in massive obstetric haemorrhage. Int J Obstet Anesth. 2007;16:40–49
  25. Knight M, Spark P, Kurinczuk JJ, Brocklehurst P. Peripartum hysterectomy in the UK: outcomes and management of associated haemorrhage. Int J Obstet Anesth. 2006;15:S8;www.npeu.ox.ac.uk/UKOSS
  26. Ahonen J, Jokela R. Recombinant factor VIIa for life threatening post-partum haemorrhage. Br J Anaesth. 2005;94:592–595
  27. Sobieszceyk S, Breborowicz GH, Platicanov V, et al. Recombinant factor VIIa in the management of postpartum bleeds. An audit of clinical use. Acta Obstet Gynecol Scand. 2006;85:1239–1247
  28. Franchini M, Lippi G, Franchi M. The use of recombinant activated factor VII in obstetric and gynaecological haemorrhage. Br J Obstet Gynaecol. 2007;114:8–15
  29. Boehlen F, Morales MA, Fontana P, et al. Prolonged treatment of massive postpartum haemorrhage with recombinant factor VIIa: case report and review of the literature. Br J Obstet Gynaecol. 2004;111:284–287
  30. Shamsi TS, Hossain N, Soomro N, et al. Use of recombinant factor VIIa for massive postpartum haemorrhage; case series and review of the literature. J Pak Med Assoc. 2005;55:512–515
  31. Price G, Kaplan J, Skowronski G. Use of recombinant factor VIIa to treat life-threatening non-surgical bleeding in a post-partum patient. Br J Anaesth. 2004;93:298–300
  32. Segal S, Shemesh IY, Blumenthal R, et al. Treatment of obstetric haemorrhage with recombinant activated factor VII (rFVIIa). Arch Gynecol Obstet. 2003;286:266–267
  33. Erhardtsen E, Nony P, Dechavanne M, et al. The effect of recombinant factor VIIa (NovoSevenTM) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0. Blood Coagul Fibrinolysis. 1998;9:741–748
  34. Dines V, Bregengaard C, Erhardtsen E, Hedner U. Recombinant human factor VIIa, (rFVIIa) in a rabbit stasis model. Thromb Res. 1992;67:233–241
  35. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost. 2004;2:1700–1708
  36. Michalska-Krzanowska G, Stasiak-Pikula E, Sajdak R. Recombinant activated factor VII: a new treatment for obstetric haemorrhage?. Anestezjologia Intensywna Therapia. 2003;35:110–112
  37. Loudon B, Smith P. Recombinant factor VIIa as an adjunctive therapy for patients requiring large volume transfusion: a pharmacoeconomic evaluation. Intern Med J. 2005;35:463–467
  38. Morris S, Ridley S, Munro V, Christensen MC. Cost effectiveness of recombinant activated factor VII for the control of bleeding in patients with severe blunt trauma injuries in the United Kingdom. Anaesthesia. 2007;62:43–52
  39. NICE. Guidance to the methods of technology appraisal. London: NICE, 2004.
  40. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence it decisions? A binary choice analysis. Health Econ. 2004;13:437–452
  41. Spahn DR, Tucci MA. Is recombinant FVIIA the magic bullet in the treatment of major bleeding?. Br J Anaesth. 2005;94:553–555

PII: S0959-289X(07)00117-3

doi: 10.1016/j.ijoa.2007.06.001

International Journal of Obstetric Anesthesia
Volume 16, Issue 4 , Pages 354-357 , October 2007

Article Tools